靶向治疗：使用分子和免疫靶向药物对抗癌症。
Targeted Therapy: Attacking Cancer with Molecular and Immunological Targeted Agents.
作者信息
Wilkes Gail M
机构信息
Oncology Nursing Consultant, Kilauea, HI, USA.
出版信息
Asia Pac J Oncol Nurs. 2018 Apr-Jun;5(2):137-155. doi: 10.4103/apjon.apjon_79_17.
Abstract
Today, personalized cancer therapy with targeted agents has taken center stage, and offers individualized treatment to many. As the mysteries of the genes in a cell's DNA and their specific proteins are defined, advances in the understanding of cancer gene mutations and how cancer evades the immune system have been made. This article provides a basic and simplified understanding of the available (Food and Drug Administration- approved) molecularly and immunologically targeted agents in the USA. Other agents may be available in Asia, and throughout the USA and the world, many more agents are being studied. Nursing implications for drug classes are reviewed.
摘要
如今，使用靶向药物的个性化癌症治疗已成为核心，并为许多人提供了个体化治疗。随着细胞DNA中基因及其特定蛋白质的奥秘被揭开，在癌症基因突变以及癌症如何逃避免疫系统的理解方面取得了进展。本文提供了对美国现有（美国食品药品监督管理局批准的）分子靶向和免疫靶向药物的基本且简化的理解。亚洲可能有其他药物，在美国乃至全世界，还有更多药物正在研究中。本文还综述了各类药物的护理注意事项。
相似文献
1
Targeted Therapy: Attacking Cancer with Molecular and Immunological Targeted Agents.靶向治疗：使用分子和免疫靶向药物对抗癌症。
Asia Pac J Oncol Nurs. 2018 Apr-Jun;5(2):137-155. doi: 10.4103/apjon.apjon_79_17.
2
Molecularly targeted cancer therapy: some lessons from the past decade.分子靶向癌症治疗：过去十年的一些经验教训。
Trends Pharmacol Sci. 2014 Jan;35(1):41-50. doi: 10.1016/j.tips.2013.11.004. Epub 2013 Dec 19.
3
Neuro-ophthalmic side effects of molecularly targeted cancer drugs.分子靶向抗癌药物的神经眼科副作用。
Eye (Lond). 2018 Feb;32(2):287-301. doi: 10.1038/eye.2017.222. Epub 2017 Oct 20.
4
Candidate cancer-targeting agents identified by expression-profiling arrays.基于表达谱芯片鉴定的候选肿瘤靶向药物。
Onco Targets Ther. 2013 Apr 23;6:447-58. doi: 10.2147/OTT.S42858. Print 2013.
5
Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).用于治疗头颈部鳞状细胞癌（HNSCC）的分子靶向药物和免疫疗法。
Discov Med. 2016 Jun;21(118):507-16.
6
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.基于肿瘤分子谱的分子靶向治疗与晚期癌症的常规治疗（SHIVA）：一项多中心、开放标签、概念验证、随机、对照的 2 期临床试验。
Lancet Oncol. 2015 Oct;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6. Epub 2015 Sep 3.
7
The folate receptor as a rational therapeutic target for personalized cancer treatment.叶酸受体作为一种合理的治疗靶点，用于癌症的个体化治疗。
Drug Resist Updat. 2014 Oct-Dec;17(4-6):89-95. doi: 10.1016/j.drup.2014.10.002. Epub 2014 Oct 8.
8
Biomarkers for personalized oncology: recent advances and future challenges.用于肿瘤个体化医学的生物标志物：最新进展与未来挑战。
Metabolism. 2015 Mar;64(3 Suppl 1):S16-21. doi: 10.1016/j.metabol.2014.10.027. Epub 2014 Oct 30.
9
[Molecularly-targeted anticancer treatments - a short appraisal].[分子靶向抗癌治疗——简要评估]
Ther Umsch. 2019 Sep;76(4):179-185. doi: 10.1024/0040-5930/a001082.
10
Molecular Genetics and the Role of Molecularly Targeted Agents in Metastatic Colorectal Carcinoma.分子遗传学及分子靶向药物在转移性结直肠癌中的作用。
J Gastrointest Cancer. 2020 Jun;51(2):387-400. doi: 10.1007/s12029-019-00272-3.
引用本文的文献
1
An examination of factors associated with disparities in clinical trial eligibility guided by the Socioecological Model.一项以社会生态模型为指导，对与临床试验资格差异相关因素的考察。
Cancer. 2025 Jul 1;131(13):e35944. doi: 10.1002/cncr.35944.
2
Advances in mRNA vaccine therapy for breast cancer research.乳腺癌研究中mRNA疫苗疗法的进展。
Discov Oncol. 2025 May 6;16(1):673. doi: 10.1007/s12672-025-02542-y.
3
NSAID-encapsulated nanoparticles as a targeted therapeutic platform for modulating chronic inflammation and inhibiting cancer progression: a review.非甾体抗炎药包裹的纳米颗粒作为调节慢性炎症和抑制癌症进展的靶向治疗平台：综述
Inflammopharmacology. 2025 Apr 26. doi: 10.1007/s10787-025-01760-8.
4
Discovery of key molecular signatures for diagnosis and therapies of glioblastoma by combining supervised and unsupervised learning approaches.通过结合有监督和无监督学习方法，发现胶质母细胞瘤诊断和治疗的关键分子特征。
Sci Rep. 2024 Nov 11;14(1):27545. doi: 10.1038/s41598-024-79391-2.
5
Overcoming Antigen Escape and T-Cell Exhaustion in CAR-T Therapy for Leukemia.克服 CAR-T 疗法治疗白血病中的抗原逃逸和 T 细胞耗竭。
Cells. 2024 Sep 23;13(18):1596. doi: 10.3390/cells13181596.
6
Recent Update on Nanocarrier(s) as the Targeted Therapy for Breast Cancer.纳米载体作为乳腺癌靶向治疗的最新进展。
AAPS PharmSciTech. 2024 Jul 3;25(6):153. doi: 10.1208/s12249-024-02867-x.
7
Exploring the Complexity and Promise of Tumor Immunotherapy in Drug Development.探索肿瘤免疫疗法在药物研发中的复杂性和前景。
Int J Mol Sci. 2024 Jun 11;25(12):6444. doi: 10.3390/ijms25126444.
8
Updates on the mechanisms of toxicities associated with monoclonal antibodies targeting growth factor signaling and immune cells in cancer.癌症中靶向生长因子信号传导和免疫细胞的单克隆抗体相关毒性机制的最新进展。
Toxicol Res. 2024 Apr 22;40(3):335-348. doi: 10.1007/s43188-024-00233-4. eCollection 2024 Jul.
9
New Carbothioamide and Carboxamide Derivatives of 3-Phenoxybenzoic Acid as Potent VEGFR-2 Inhibitors: Synthesis, Molecular Docking, and Cytotoxicity Assessment.新型3-苯氧基苯甲酸碳硫酰胺和羧酰胺衍生物作为强效VEGFR-2抑制剂：合成、分子对接及细胞毒性评估
Curr Cancer Drug Targets. 2025;25(4):412-430. doi: 10.2174/0115680096307334240429050730.
10
Outcomes of physical exercises on initiation, progression, and treatment of breast cancer.体育锻炼对乳腺癌的发生、发展和治疗的影响。
Cell Commun Signal. 2024 May 7;22(1):260. doi: 10.1186/s12964-024-01634-6.
本文引用的文献
1
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.免疫疗法毒性管理：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142. doi: 10.1093/annonc/mdx225.
2
The Why, what, and How of the New FACT standards for immune effector cells.新的免疫效应细胞 FACT 标准的由来、内容和方法。
J Immunother Cancer. 2017 Apr 18;5:36. doi: 10.1186/s40425-017-0239-0. eCollection 2017.
3
Indicators of responsiveness to immune checkpoint inhibitors.免疫检查点抑制剂的反应指标。
Sci Rep. 2017 Apr 11;7(1):807. doi: 10.1038/s41598-017-01000-2.
4
Reviving the guardian of the genome: Small molecule activators of p53.唤醒基因组的守护者：p53 的小分子激活剂。
Pharmacol Ther. 2017 Oct;178:92-108. doi: 10.1016/j.pharmthera.2017.03.013. Epub 2017 Mar 27.
5
Cytokine Release Syndrome: Inpatient Care for Side Effects of CAR T-Cell Therapy
.细胞因子释放综合征：CAR T细胞疗法副作用的住院治疗
Clin J Oncol Nurs. 2017 Apr 1;21(2 Suppl):29-34. doi: 10.1188/17.CJON.S2.29-34.
6
PARP inhibitors: Synthetic lethality in the clinic.聚（ADP-核糖）聚合酶抑制剂：临床中的合成致死性
Science. 2017 Mar 17;355(6330):1152-1158. doi: 10.1126/science.aam7344. Epub 2017 Mar 16.
7
Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.针对 EGFR-RAS-RAF 通路的癌症治疗耐药性：MEK 的作用。
Cancer Treat Rev. 2017 Feb;53:61-69. doi: 10.1016/j.ctrv.2016.12.001. Epub 2016 Dec 30.
8
HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and Outcomes.在社区肿瘤学实践环境中接受帕妥珠单抗治疗的HER2阳性转移性乳腺癌患者：治疗模式与结局
Drugs Real World Outcomes. 2017 Mar;4(1):1-7. doi: 10.1007/s40801-016-0102-5.
9
Anti-tumor activity of metformin: from metabolic and epigenetic perspectives.二甲双胍的抗肿瘤活性：从代谢和表观遗传学角度探讨
Oncotarget. 2017 Jan 17;8(3):5619-5628. doi: 10.18632/oncotarget.13639.
10
What do you mean, "epigenetic"?你说的“表观遗传”是什么意思？
Genetics. 2015 Apr;199(4):887-96. doi: 10.1534/genetics.114.173492.
Zotero 插件